Gufic BioSciences Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Gufic BioSciences Ltd trades at ₹382, in a confirmed uptrend and 3 weeks into that stage. That is +13.5% against its own 200-day average. It sits at 89% of a 52-week range of ₹279 to ₹394. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 14 straight weeks.

Today the stock is in a confirmed uptrend — week 3 of stage 2, confirmed. At ₹382 it trades +13.5% versus its 200-day average and sits at 89% of its 52-week range (₹279–₹394).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +759% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 14 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 84th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Gufic BioSciences Ltd trades at 59.2× P/E, at the pricey end of its own range (84th percentile). Its long-run median P/E is 54.2×, measured across 2.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 59.2× is at the pricey end of its own range (84th percentile), against a long-run median of 54.2× measured over 2.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved −7.9% against a −0.7% price move — the price outran earnings, pushing the multiple UP its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Gufic BioSciences Ltd reads as mixed on its fundamental arc. Mixed — profit and EPS growth are shrinking while ROCE holds at 15.3% — falling growth against firm returns, so no single stage word fits yet. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

40.8/100 — rank 33 of 43 in Pharma - Formulators · 90% evidence confidence

Gufic BioSciences Ltd scores 40.8 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 33. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 19.7 + 11.4 + 1.9 + 7.8 = 40.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Gufic BioSciences Ltd reported ₹252 Cr of revenue in the Mar 26 quarter, +22.9% year on year. That is the 6th straight quarter of year-on-year growth. Over 2 years it has compounded at 8.2% a year. The last full year, FY26, came in at ₹944 Cr. The last four reported quarters add to ₹944 Cr.

Gufic BioSciences Ltd reported ₹252 Cr of revenue in the Mar 26 quarter, +22.9% year on year. That is the 6th straight quarter of year-on-year growth. Over 2 years it has compounded at 8.2% a year. The last full year, FY26, came in at ₹944 Cr. The last four reported quarters add to ₹944 Cr.

FY26 revenue came in at ₹944 Cr (+15.1% on the year), capping 2 years at 8.2% compound. The latest quarter (Mar 26) printed ₹252 Cr, +22.9% year on year — the 6th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +15.1% growth against the decade's 8.2% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +15.1% over the last 4 quarters against +8.2%/yr over the last 8 — accelerating; TTM profit −8.6% vs −13.7%/yr — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 19.0% this quarter (+6.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Gufic BioSciences Ltd's operating margin is 19.0% in the Mar 26 quarter, +6.0 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 16.0% to 19.0%. The current quarter sits inside that band.

Gufic BioSciences Ltd's operating margin is 19.0% in the Mar 26 quarter, +6.0 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 16.0% to 19.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 19.0%, +6.0 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 16.0%–19.0%.

Why the margin moved: operating margin went +5.9 pp year on year while gross margin went −1.9 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins held — did that reach the bottom line? Next: profit +175.0% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Gufic BioSciences Ltd earned ₹22.0 Cr of net profit in the Mar 26 quarter, +175.0% year on year. Full-year FY26 profit was ₹64.0 Cr. The 2-year compound rate is −13.7%. That is 8.7% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr.

Gufic BioSciences Ltd earned ₹22.0 Cr of net profit in the Mar 26 quarter, +175.0% year on year. Full-year FY26 profit was ₹64.0 Cr. The 2-year compound rate is −13.7%. That is 8.7% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr.

Mar 26 profit was ₹22.0 Cr, +175.0% year on year. On the full year, FY26 printed ₹64.0 Cr (−8.6%), and the 2-year compound rate is −13.7%.

Why profit moved: revenue contributed +22.9% and the margin +6.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +19.4% vs revenue +15.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

→ Profit rose — but did the cash follow? Next: 73% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 73% of Gufic BioSciences Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹45.0 Cr of operating cash against ₹64.0 Cr of profit. After ₹16.0 Cr of capital spending, ₹29.0 Cr was left as free cash.

FY26: operating cash of ₹45.0 Cr against reported profit of ₹64.0 Cr, leaving free cash of ₹29.0 Cr after ₹16.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 73% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 73%: the cash cycle stretched 43 days between FY24 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: conversion is below par and the cash cycle has stretched 43 days — the next section's job is to find where the cash is stuck.

→ So follow the cash to where it goes. Next: the 224-day cycle, in money terms.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Gufic BioSciences Ltd's cash conversion cycle runs 224 days in FY26, up from 181 days in FY24. Capital spending ran ₹99.0 Cr over the last 2 years. At FY26 sales of ₹944 Cr each day of that cycle holds about ₹2.6 Cr, so roughly ₹579 Cr sits inside the business at any moment.

FY26: debtors at 115 days, inventory at 281 days — roughly 9.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 224 days, looser than FY24's 181.

The full loop: cash goes out to suppliers and production on day 0; stock waits 281 days to sell; customers pay about 115 days after that; and suppliers themselves are paid at 172 days — netting out to the 224-day cycle.

In money terms: at FY26 sales of ₹944 Cr, each day of the cycle holds about ₹2.6 Cr — so the 224-day loop keeps roughly ₹579 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹99.0 Cr over the last 2 fiscal years against ₹52.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹22.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 12% and the ROIC − WACC spread is −2.6 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Gufic BioSciences Ltd earns a ROCE of 12% in FY26. Return on invested capital clears the cost of that capital by −2.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 6.8% net margin on 0.70× asset turns.

FY26 ROCE is 12%.

🚨 Why the return is what it is — the wiring (FY26): 6.8% net margin × 0.70× asset turns × 2.02× balance-sheet leverage ≈ 9.6% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 9.4% − 12.0% = a −2.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.61.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Gufic BioSciences Ltd carries total debt of ₹405 Cr against shareholder equity of ₹665 Cr as of Mar 26, a debt-to-equity of 0.61. On the annual view that ratio went from 0.24 in FY22 to 0.61 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹405 Cr against shareholder equity of ₹665 Cr — a debt-to-equity of 0.61. On the annual view, debt-to-equity went from 0.24 (FY22) to 0.61 (FY26). Read the returns on this page with that leverage in mind.

→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 1.3 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 1.3 points of Gufic BioSciences Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 3.7% of the company. Foreign institutions moved +0.2 points over the same window, to 0.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +1.3 points over 8 quarters to 3.7%; Foreign institutions: +0.2 points over 8 quarters to 0.5%; Promoters: +0.0 points over 8 quarters to 72.5%.

Why the register moved: domestic institutions drove it (+1.3 points) — steady accumulation by institutions reading the same numbers this page reads.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Gufic BioSciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions